Correlation between lncRNAs with human molecular chaperons in cancer immunopathogenesis and drug resistance

IF 4.8 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2024-10-14 DOI:10.1016/j.intimp.2024.113309

引用次数: 0

Abstract

The development of cancer immunology heavily relies on the interaction between long non-coding RNAs (lncRNAs) and molecular chaperones. By participating in gene regulation, lncRNAs interact with molecular chaperones, which play a critical role in protein folding and stress responses, to influence oncogenic pathways. This interaction has an impact on both the immune cells within the tumor microenvironment and the tumor cells themselves. Understanding these mechanisms provides valuable insights into innovative approaches for diagnosis and treatment. Targeting the lncRNA-chaperone axis has the potential to strengthen anti-tumor immunity and enhance cancer treatment outcomes. Further research is necessary to uncover specific associations, identify biomarkers, and develop personalized therapies aimed at disrupting this axis, which could potentially revolutionize cancer diagnosis and treatment.

查看原文本刊更多论文

lncRNA 与人类分子伴侣在癌症免疫发病机制和耐药性中的相关性

癌症免疫学的发展在很大程度上依赖于长非编码 RNA（lncRNA）与分子伴侣之间的相互作用。通过参与基因调控，lncRNA 与在蛋白质折叠和应激反应中发挥关键作用的分子伴侣相互作用，从而影响致癌途径。这种相互作用对肿瘤微环境中的免疫细胞和肿瘤细胞本身都有影响。了解这些机制为创新诊断和治疗方法提供了宝贵的见解。以 lncRNA-伴侣蛋白轴为靶点有可能加强抗肿瘤免疫力，提高癌症治疗效果。有必要开展进一步的研究，以揭示特定的关联、确定生物标志物并开发旨在破坏该轴的个性化疗法，从而有可能彻底改变癌症的诊断和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.